Is Dostinex Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use Dostinex? Is Dostinex safe for nursing mother and child? Does Dostinex extracts into breast milk? Does Dostinex has any long term or short term side effects on infants? Can Dostinex influence milk supply or can Dostinex decrease milk supply in lactating mothers?

• DrLact safety Score for Dostinex is 5 out of 8 which is considered Unsafe as per our analyses.
• A safety Score of 5 indicates that usage of Dostinex may cause serious side effects in breastfed baby.
• Our study of different scientific research indicates that Dostinex may cause moderate to high side effects or may affect milk supply in lactating mother.
• Our suggestion is to use safer alternate options rather than using Dostinex .
• It is recommended to evaluate the advantage of not breastfeeding while using Dostinex Vs not using Dostinex And continue breastfeeding.
• While using Dostinex Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
• Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Ergot derivative alkaloid which is used to suppress lactation by inhibiting Prolactin release. Also used with levodopa for treatment of Prolactinoma and Parkinson disease. No untoward effects have been reported in breastfed infants of mothers who were treated (or erroneously had received medication) and decided to resume breastfeeding. Non-pharmacological methods used to suppress lactation are as effective as pharmacological ones.

Dostinex is usually not used during breastfeeding because it suppresses lactation. The U.S. Food and Drug Administration considers Dostinex to be not indicated to suppress lactation because the similar drug bromocriptine has caused hypertension, stroke, seizures and psychosis when used for this purpose. Dostinex's use in other conditions has caused side effects similar to other dopamine agonists, such as bromocriptine. Whether rare cases of severe adverse effects occur with Dostinex as with bromocriptine cannot be determined because of the small number of postpartum patients treated in clinical trials to date. However, limited experience from clinical trials indicates that a single oral dose of 1 mg of Dostinex causes fewer side effects (usually headache, dizziness and nausea) than 14 days of bromocriptine and is at least as effective when used to suppress unwanted lactation. Some experts recommend Dostinex as a safer alternative to bromocriptine for lactation suppression, but others do not.[1][2][3] The disadvantage of Dostinex is that it has a half-life of about 68 hours, which means that any adverse effects will persist for a prolonged period of time. Women treated with Dostinex for pituitary adenomas who become pregnant can breastfed their infants with no apparent risk of recurrence. A treatment scheme has been reported for mothers with hypergalactia that uses low doses of Dostinex to decrease milk supply.[4]

Seventeen women who did not wish to breastfeed received a placebo or a single oral dose of Dostinex 400 mcg or 600 mcg on day 2 or 3 postpartum. Use of other lactation suppressing measures (e.g., breast binding, lack of nipple stimulation) was not mentioned. Blood samples were taken periodically over the next 96 hours. In the 7 women who received 400 mcg, plasma prolactin levels were decreased at 24 and 48 hours, but 4 developed breast engorgement. In the 5 women who received 600 mcg, plasma prolactin levels were decreased by 12 hours and persisted up to 96 hours and none developed breast engorgement. Some women had minor decreases in blood pressure, but no other adverse effects were reported.[5] Thirty-two women who did not wish to breastfeed were given placebo or Dostinex 400, 600 or 800 mcg within 24 hours after delivery in a double-blind trial. Use of other lactation suppressing measures (e.g., breast binding, lack of nipple stimulation) was not mentioned. Lactation was prevented in 4 of 8 women who received the 400 mcg dose and all women who received the 600 or 800 mcg dose. Only 1 of 8 women receiving placebo had cessation of lactation by day 14 postpartum. Serum prolactin levels collected on days 2, 3 and 4 of treatment were decreased significantly in all women who received Dostinex, but the decreases were not statistically different among the various doses.[6] A prospective, randomized, double-blinded study compared the effects of a single dose of Dostinex 0.5, 0.75 or 1 mg in 40 women each and to 20 women who received a placebo. The drug was given in the first 24 hours postpartum and use of other lactation suppressing measures (e.g., breast binding, lack of nipple stimulation) was not mentioned. The adequacy of lactation suppression on day 14 postpartum was dose-related, with excellent results in 18 patients who receive 0.5 mg, 28 who received 0.75 mg and 36 who received 1 mg. Serum prolactin levels collected during 13 days of treatment were decreased significantly in all women who received Dostinex, but the decreases were not statistically different among the various doses. Adverse effects included occasional dizziness and headache between days 1 and 3 after the dose.[7] In a single-blind trial, 36 women were given either a single oral dose of Dostinex 1 mg or oral bromocriptine 2.5 mg twice daily for 14 days, starting about 50 hours after cesarean section. Use of other lactation suppressing measures (e.g., breast binding, lack of nipple stimulation) was not mentioned. Another 13 women who were breastfeeding after cesarean section served as controls. Both Dostinex and bromocriptine suppressed baseline serum prolactin by about 90% compared to baseline and control women within 3 days; this persisted at least through day 7, but somewhat rebounded by day 14. Suppression of lactation as measured by milk secretion, tenderness, and engorgement was equal between the 2 treatment groups. Lactation suppression was complete in 17 of 18 women who received Dostinex and 16 of 18 women who received bromocriptine, although the response was more rapid with Dostinex. Adverse events from Dostinex were fewer in number than with bromocriptine and consisted of occasional headache lasting 2 days, dizziness, and vomiting.[8] A well-designed and evaluated double-blind study compared oral Dostinex 1 mg in a single dose (n = 136) to oral bromocriptine 2.5 mg twice daily for 14 days (n = 136) in women within 27 hours postpartum. Some women in each group (Dostinex n = 18; bromocriptine n = 16) received an ergot alkaloid or oral contraceptive postpartum. Symptoms of milk production and engorgement were recorded by the women and serum prolactin levels were measured on 3 occasions during the first 2 to 3 weeks postpartum. Dostinex was at least as effective as bromocriptine, with complete success in 78% of Dostinex patients and 69% of bromocriptine patients. The rate of rebound lactation was much higher in bromocriptine patients (24%) than in Dostinex patients (5%). Serum prolactin was suppressed in both groups, but rebound was more common with bromocriptine on days 15 and 21. Adverse effects were numerically, but not statistically less frequent in Dostinex patients, with the most frequent being dizziness, headache, nausea and epigastric pain.[9] Dostinex was evaluated for lactation suppression in a prospective, but nonrandomized, unblinded trial. Women who were within 24 hours postpartum were given a single 1 mg dose (n = 54); those who were beyond 24 hours were given 0.25 mg twice daily for 2 days (n = 46). Only composite results were given for the entire group of 100 women. Mean serum prolactin dropped from 181.4 mcg/L (range 153 to 213 mcg/L) on the first day to 12.5 mcg/L (range 0.9 to 37 mcg/L) on day 4, and 18.2 mcg/L (range 2 to 36.2 mcg/L) on day 14 after the dose. Lactation was completely inhibited in 92% of women; 8 women required a second doses of 1 mg to inhibit